Specific symptoms that were noted - was the reaction consistent with an IgE-mediated reaction?
Timing of onset of the symptoms relative to the administration of the vaccine
Other exposures to possible allergens (e.g. NSAIDs)
Any information from office visits/emergency department visits
Treatment that was administered
Duration of symptoms, time course of resolution
Previous vaccine reaction history
History of other atopic disease, including food allergy, drug allergy, atopic dermatitis, asthma, and allergic rhinitis
Specific vaccine(s) that was administered, including the manufacturer and lot number
Will the patient need additional doses of this vaccine or other vaccines with common constituents?
Should be classified according to the extent (local, systemic) and the timing of the reaction (immediate, non-immediate). The frequency (common, rare) and severity (minor, moderate, major) of the reaction should also be noted.
Vaccine Reaction Types and Clinical Implications
Notes
Small local reactions
Tissue damage by the puncture itself and injection of foreign material into tissues is responsible for a non-specific inflammatory reaction of the skin
Longer needles being associated with a lower rate of local reactions, therefore proper needle length should be used
Self-resolving, not a contraindication to revaccination
Large local reactions
Less common overall than SLR; may be more likely with vaccines containing toxoids or adjuvants and with additional doses of the same vaccine
LLR types:
Typical LLR occurs 24-72 h after injection, possibly due to antigen/adjuvant TLR-induced inflammation and/or an antibody-mediated Arthus-type reaction
Another pattern of LLR is benign reactive edema (often WITHOUT pain, reduced limb movement, redness, fever) occurring <24 h, which can be extensive and extend to elbow or knee; can occur with first injection
Both types of LLRs are self-resolving, and are not a contraindication to revaccination
Lieberman: to help decrease risk of LLR recurrence, consider dividing vaccine dose over days, e.g. 0.5 mL vaccine given as 0.1 mL daily x 5 days
If an Arthrus reaction is suspected, consider checking IgG titers and delaying the next vaccination (vs. revaccination as usual)
Systemic reactions
Normal systemic symptoms occur in 5-13%, most often fever, irritability, drowsiness, and rash; result from non-specific mechanisms and do not recur with future boosters
Mild generalized urticarial reactions of delayed onset often result from a non-specific degranulation of mast cells and do not contraindicate (re)vaccination; though controversial, oral antihistamines can be given for 48 h to ensure patient comfort after administration of the vaccine
IgE-mediated reactions, anaphylaxis - very rare, 1-3 per million doses of vaccine, must be evaluated prior to revaccination
Other immunologic reactions (serum sickness-like, HSP, specific organ damage) are even rarer than IgE-mediated reactions
Potential Vaccine Allergens and Clinical Implications (Caubet)
Microbial components themselves (tetanus and diphtheria toxoids) have been reported as allergens
Gelatin (stabilizer)
Egg proteins (remnants from vaccine production)
Aluminum (adjuvant)
Persistent itching, subcutaneous nodules, or granulomas at the injection site after vaccination with Al-adsorbed vaccines have been described but is considered to be rare
In aluminum contact-sensitized (i.e. positive patch test) patients requiring a vaccine containing Al, it should be administered deep enough as IM injection may prevent the formation of granulomas; some patients may develop local or systemic contact dermatitis reactions
Thimerosal (preservative)
Found in fewer vaccines due to mercury content
Vast majority of patients with positive patch test to thimerosal tolerate thimerosal-containing vaccines uneventfully, but it should still be avoided if possible to decrease risk of local reactions
Phenoxyethanol, and formaldehyde (preservatives)
Potential contact allergens
Latex - see below
Antibiotics - theoretical risk of IgE-mediated reactions but never reported, more likely to cause contact dermatitis reactions (especially neomycin)
Vaccination is not contraindicated in patients with contact allergy to neomycin, as the risk of a mild local reaction is outweighed by the vaccine benefit
Committee on Infectious Diseases of the AAP no longer considers contact hypersensitivity to neomycin a contraindication to vaccination
Yeast - Hep B and HPV vaccines are manufactured using recombinant strains of Saccharomyces cerevisiae (common bakers’ yeast) and contain residual yeast proteins
In patients with clinical reactivity to Baker’s or Brewer’s yeast and sensitized to S. cerevisiae, skin tests with yeast-containing vaccines should be performed; In case of positive results, the vaccine can still be given in graded doses
Milk - see below
Dextran - implicated in severe immediate reactions to BCG (particularly during the neonatal period), and to some MMR vaccines (withdrawn from market)
Reactions associated with presence of IgG to dextran; hypothesized that complement activation and anaphylatoxin release were the main mechanisms
Note that NSAIDs are often given concomitantly with vaccines
Practice Parameter Algorithm
Note 1. Are nature and timing of reaction consistent with anaphylaxis?
Probable Anaphylactic Reaction: reaction occurring within 4 hours of vaccine administration to include signs and/or symptoms from more than 1 of the following systems:
Cardiovascular: hypotension, tachycardia, palpitations, light-headedness, loss of consciousness (Note: hypotension or loss of consciousness with pallor and bradycardia is much more likely a vasovagal reaction.)
GI: cramping, nausea, vomiting, diarrhea
Possible Anaphylactic Reaction: Signs and/or symptoms from only 1 system (as above) or signs and/or symptoms from more than 1 system (as above) but occurring more than 4 hours after vaccination
Note 2. Skin tests with vaccine and components including gelatin, egg, chicken and/or yeast vaccine skin tests:
Prick test with full strength vaccine (consider 1:10 or 1:100 dilution if history of life-threatening reaction)
If SPT with full strength vaccine negative, intradermal test with 0.02 mL vaccine 1:100 (which is thought to be non-irritating for vaccines; at 1:100 irritant reactions seen in 5% for DT and DTaP and 15% for influenza)
Note:
Vaccine skin tests are unstandardized and may cause false positive or negative reactions
Delayed responses to vaccine skin tests are common, most likely representing prior immunity, and should not raise concern in the evaluation of IgE-mediated vaccine allergy
If ID is negative, an IgE-mediated allergy to any vaccine constituent is very unlikely and the vaccine can be administered in the usual manner, but the patient should be observed for at least 30 min afterward
Vaccine component/food skin tests:
Egg - SPT with commercial extracts of whole egg or egg white (influenza and yellow fever), chicken (yellow fever )
Yeast - SPT with Saccharomyces cerevisiae yeast (Hep B and HPV4)
Gelatin - SPT with sugared gelatin (e.g. Jell-O®: dissolve 1 teaspoon (5 grams) of gelatin powder in 5 mL normal saline)
Vaccines that contain gelatin: DTaP (some brands), influenza (some brands), Japanese encephalitis, MMR/ MMRV (given together or in their individual components), rabies (some brands), typhoid (oral), yellow fever, zoster
Reported cases of gelatin tolerated orally but not when injected
Strong association between gelatin allergy and HLA-DR9, which is particularly prevalent in Japan
Association between gelatin and alpha-gal allergy has also been established
Milk - case report of milk proteins in DTP vaccines (DTaP, Tdap) causing anaphylaxis in children with severe cow's milk allergy
Latex - There is a theoretical risk of reaction in latex allergic individuals due to natural rubber latex stoppers/plungers
Thimerosal, neomycin - IgE-mediated reactions to these substances is very rare/unlikely; no commercially available skin test reagents or sIgE tests are available for these
Note 3. If fewer than the recommended number of doses received, consider measuring level of IgG antibodies to immunizing agent. If at a level associated with protection from disease, consider withholding additional doses although magnitude and duration of immunity may be less than if all doses received.
Note 4. Vaccine administration in graded doses
If vaccine or vaccine component skin tests are positive, and an alternative is not available, the vaccine should still be administered in graded doses
For a vaccine where usual dose is 0.5 mL, administer graded doses of vaccine at 15 minute intervals: 0.05 mL of 1:10 dilution, 0.05 mL of full strength, 0.10 mL of full strength, 0.15 mL of full strength, 0.20 mL of full strength
Wood: considered on a case by case basis, recognizing that a graded dose protocol still carries the risk of anaphylaxis. This should be conducted with informed consent and only in a setting prepared to treat severe allergic reactions should one occur.
If vaccine or vaccine component skin test is negative, give in usual manner and observe for 30 minutes
Table of Contents
Influenza Vaccine Adverse Reactions
Other Vaccines Adverse Reactions
Key Parts of Medical History
Vaccine Reaction Types and Clinical Implications
Potential Vaccine Allergens and Clinical Implications (Caubet)
Practice Parameter Algorithm
Note 1. Are nature and timing of reaction consistent with anaphylaxis?
Note 2. Skin tests with vaccine and components including gelatin, egg, chicken and/or yeast vaccine skin tests:
Note 3. If fewer than the recommended number of doses received, consider measuring level of IgG antibodies to immunizing agent. If at a level associated with protection from disease, consider withholding additional doses although magnitude and duration of immunity may be less than if all doses received.
Note 4. Vaccine administration in graded doses
Wood Algorithm
Vaccine Allergens and Excipients
References